|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The naturally occurring oncolytic herpes simplex virus canerpaturev (C-REV), formerly HF10, proved its therapeutic efficacy and safety in multiple clinical trials against melanoma, pancreatic, breast, and head and neck cancers.
|
31193737 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue.
|
29801474 |
2018 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
HF10 is an oncolytic herpes simplex virus-1 with a unique genomic structure that has non-engineered deletions and insertions accompanied by frame-shift mutations, in contrast to the majority of engineered OVs.
|
28770166 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
|
25156870 |
2015 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated the efficacy of HF10, a herpes simplex virus type 1 (HSV-1) mutant, in combination with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in human pancreatic cancer xenograft models.
|
24170435 |
2014 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
RH2 is a neurovirulent γ134.5 gene-deficient herpes simplex virus type 1 (HSV-1) with a lytic ability in human squamous cell carcinoma (SCC) cells; it is related to spontaneously occurring HSV-1 mutant HF10.
|
23887644 |
2013 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
We have developed replication-competent attenuated herpes simplex virus type 1 (HSV-1) mutants, named HF10 and Hh101, which have been evaluated for their oncolytic activities.
|
20885447 |
2011 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous reports have also shown that a combination of HF10 and paclitaxel (TAX) was more efficacious than either regimen alone for some types of malignant tumors [S. Shimoyama, F. Goshima, O. Teshigahara, H. Kasuya, Y. Kodera, A. Nakao, et al., Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models, Hepatogastroenterology 54 (2007) 1038-1042].
|
19604626 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
|
18226503 |
2008 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
|
17346108 |
2007 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
|
16923721 |
2006 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
|
16286150 |
2005 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
We applied a spontaneously generated, highly attenuated herpes simplex virus (HSV) type-1 clone, HF10, to the treatment of breast cancer.
|
14696086 |
2004 |